The Latest Cardiac and Vascular News
BOSTON–(BUSINESS WIRE)–Results of a three-year, investigator-led study of all Impella-supported patients treated at 109 hospitals in Japan (n=1,344) show 30-day survival rates of 81% for AMI cardiogenic shock (AMICS) patients. The study is an update to a 2020 interim analysis and was presented at the 2022 Transcatheter Cardiovascular Therapeutics (TCT) conference taking […]
FDA Also Approves and Closes RECOVER III Post-Approval Study DANVERS, Mass.–(BUSINESS WIRE)–Abiomed (Nasdaq: ABMD) announces two approvals from the U.S. Food and Drug Administration (FDA) related to clinical research of Impella heart pumps in acute myocardial infarction (AMI) cardiogenic shock patients. The FDA has approved the on-label RECOVER IV randomized controlled […]
Interim data from the cardiomyopathy arm of the Phase 1 study of NTLA-2001 showed deep and sustained mean serum transthyretin (TTR) reductions of 93% and 92% at 0.7 mg/kg and 1.0 mg/kg doses, respectively, at day 28 NTLA-2001 was generally well-tolerated at both dose levels Intellia to discuss data at […]
New Heart Valve Durability tester with Automatic Dual Control technology debuts at the 34th Transcatheter Cardiovascular Therapeutics (TCT), the annual scientific symposium of the Cardiovascular Research Foundation. “Introducing a New Generation of Durability Testers” VICTORIA, BC, Sept. 16, 2022 /PRNewswire/ — ViVitro Labs, the industry-leading provider of cardiovascular device test equipment and related […]
Three leading U.S. interventional cardiologists attend initial cases as company prepares to expand its clinical program LOS GATOS, Calif., Sept. 16, 2022 /PRNewswire/ — Supira Medical, Inc., a Shifamed portfolio company focused on developing the next-generation solution for mechanical circulatory support, announced today it has initiated its first-in-human clinical study performed by principal […]
IRVINE, Calif., Sept. 15, 2022 /PRNewswire/ — Edwards Lifesciences Corporation ( NYSE: EW), today announced the company’s PASCAL Precision transcatheter valve repair system for transcatheter edge-to-edge repair (TEER) has received FDA approval for the treatment of patients with degenerative mitral regurgitation (DMR). “Patients suffering with debilitating symptoms as a result of degenerative mitral regurgitation represent a […]
Leadership team reinforced for next phase in Protembis’ clinical and regulatory growth trajectory AACHEN, Germany–(BUSINESS WIRE)–Protembis GmbH, a privately-held emerging cardiovascular medical device company, announced today the appointment of highly experienced and successful serial entrepreneur and medical device executive Azin Parhizgar (Ph.D.) as an Independent Member and Chairwoman of the […]
VANCOUVER and MINNEAPOLIS, Sept. 15, 2022 (GLOBE NEWSWIRE) — via NewMediaWire – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today commented on the Centers for Medicare and Medicaid Services (“CMS”) development of new codes for the diagnosis and tracking of refractory angina. The new codes will be utilized in the current, 10th […]
MORRISVILLE, N.C., Sept. 15, 2022 (GLOBE NEWSWIRE) — Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today announced that the Company is evaluating alternative strategic paths focused on maximizing shareholder value. […]
10th annual MedAxiom cardiovascular provider compensation and production report reveals year-over-year comparisons and decade trends NEPTUNE BEACH, Fla.–(BUSINESS WIRE)–MedAxiom, the premier source for cardiovascular organizational performance solutions, has released its 10th annual that includes data from the largest number of providers since its debut. The report features a special section on 10-year […]
